Home › Compare › JRJRQ vs ABBV
JRJRQ yields 2000000.00% · ABBV yields 3.06%● Live data
📍 JRJRQ pulled ahead of the other in Year 1
Combined, JRJRQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JRJRQ + ABBV for your $10,000?
JRjr33, Inc., together with its subsidiaries, operates direct-to-consumer brands in the United States and internationally. It operates three segments: home décor, nutritional and wellness, and gourmet food. The company offers hand-crafted baskets and a line of products for the home, including pottery, cleaning, beauty, outdoor, customizable vinyl expressions for display, wrought iron, and fabric accessories; hand-crafted spices, oils, dip mixes, dukkahs, baking mixes, vinegars, and other food products; and nutritional supplements and skin care products. It also publishes a monthly magazine, as well as provides stationery and paper gifts; tools for women; and health and beauty products, electricals, housewares, Christmas products, toys, gifts, garden products, and personalized gifts. JRjr33, Inc. sells its products directly to customers, as well as through independent sales representatives, Internet, mail, telephone, and fax. JRjr33, Inc. was formerly known as CVSL Inc. and changed its name to JRjr33, Inc. in March 2016. JRjr33, Inc. is based in Dallas, Texas. On October 26, 2018, the voluntary petition of JRjr33, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on June 29, 2018.
Full JRJRQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.